NCT06500637 - TB006 for Autism Spectrum Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

Autism Spectrum Disorder

Interventions

DRUG

TB006

TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).

Trial Locations (2)

85050

RECRUITING

Rossignol Medical Center, Phoenix

92656

RECRUITING

Rossignol Medical Center, Aliso Viejo

All Listed Sponsors

collaborator

Autism Discovery and Treatment Foundation

UNKNOWN

lead

Rossignol Medical Center

OTHER